Oliver Davies

Private Equity @ Econ Climate Fund

Delhi, India

About

Email : [email protected] I’m an Investment Analyst at Econ Climate Fund, working on financial modelling, valuation and due diligence for climate infrastructure and clean-energy transactions. My career so far has blended cross-border experience in investment banking and venture capital, giving me exposure to both later-stage M&A in healthcare/pharma and early-stage funding rounds in emerging markets. Alongside this, I completed an MSc in Finance at a Russell Group university, with the aim of broadening my investment lens across different geographies and capital structures. To build genuine practical skills rather than just academic knowledge, I moved to India to work on live deals. At Allegro Capital, a boutique investment bank headquartered in Bangalore, I supported transactions in the pharmaceutical and life sciences sectors, contributing to financial models, valuation work and market analysis on both domestic and cross-border mandates. More recently, as a Junior Associate at Turbostart, I helped set up a new investment banking vertical within the venture platform – preparing sector research, positioning materials and early-stage financial models, while working directly with founders and investors across mobility, deep-tech and consumer businesses. Across these roles, I’ve focused on turning complex financial and commercial information into clear, decision-ready insights for investment committees and management teams.

Experience

  • Investment Analyst at Econ Climate Fund
    Dec 2025 - Present · 7 mos

  • Junior Associate, Venture Capital & Private Equity at Turbostart
    Dec 2024 - Apr 2025 · 5 mos

  • Hawksmoor (London Area, United Kingdom)
    • Chef De Partie
      Apr 2022 - Jun 2024 · 2 yrs 3 mos

      Part-time culinary background whilst studying.

    • Commis Chef
      Dec 2021 - Apr 2022 · 5 mos

  • Insight Day at Deloitte
    Apr 2024 - Apr 2024 · 1 mo

  • Investment Banking Intern at Allegro Capital Advisors
    Jun 2023 - Sep 2023 · 4 mos

    M&A - Healthcare & Pharamaceuticals